Darolutamide:a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer
作者机构：GU Medical OncologyInova Schar Cancer InstituteFairfaxVA 22031USA
出 版 物：《Asian Journal of Andrology》 (亚洲男性学杂志（英文版）)
年 卷 期：2020年第22卷第1期
页 面：76-78页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：metastatic metastasis resistant
摘 要：ARAMIS is an international PhaseⅢtrial demonstrating the beneficial role of darolutamide,a novel anti-androgen that has been found to prolong metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer.
维普期刊数据库